Effects of sulfonylureas on mitochondrial ATP-sensitive K+ channels in cardiac myocytes: Implications for sulfonylurea controversy

Diabetes/Metabolism Research and Reviews

Volumn 22, Issue 5, 2006, Pages 341-347

  Sato, Toshiaki ^a   Nishida, Hirofumi ^a   Miyazaki, Masaru ^a   Nakaya, Haruaki ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium overload; Cardioprotection; Diabetes; KATP channel; Mitochondria; Sulfonylurea

Indexed keywords

2,4 DINITROPHENOL; 5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CALCIUM ION; DIAZOXIDE; FLAVOPROTEIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; OUABAIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE ANALYSIS; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE WALL; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RABBIT; STATISTICAL SIGNIFICANCE;

ANIMALS; CARDIOTONIC AGENTS; FLAVOPROTEINS; FLUORESCENCE; HEART VENTRICLES; HYPOGLYCEMIC AGENTS; MEMBRANE POTENTIALS; MUSCLE CELLS; OXIDATION-REDUCTION; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; RABBITS; SULFONYLUREA COMPOUNDS;

EID: 33749003103     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.621     Document Type: Article

References (37)

1. Klimt CR, Knatterud GL, Meinert CL, Prout TE. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970; 19: 747-830.
2. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972; 21: 976-979.
3. ATP blockade in type II diabetes and preconditioning in cardiovascular disease: time for reconsideration. Circulation 1996; 94: 2297-2301.
4. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
5. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 1113-1151.
6. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992; 70: 223-233.
7. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103: 3111-3116.
8. + channels: possible mechanism of cardioprotection. Circ Res 1997; 81: 1072-1082.
9. Liu Y, Sato T, O'rourke B, Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998; 97: 2463-2469.
10. + channels. J Biol Chem 1988; 263: 7933-7936.
11. Zhang DX, Chen YF, Campbell WB, Zou AP, Gross GJ, Li PL. Characteristics and superoxide-induced activation of reconstituted myocardial mitochondrial ATP-sensitive potassium channels. Circ Res 2001; 89: 1177-1183.
12. + current of guinea pig ventricular cells through the activation of protein kinase C. Circ Res 1992; 71: 1441-1446.
13. + channels by protein kinase C. Circ Res 1998; 83: 110-114.
14. Suzuki M, Li RA, Miki T, et al. Functional roles of cardiac and vascular ATP-sensitive potassium channels clarified by Kir6.2-knockout mice. Circ Res 2001; 88: 570-577.
15. 2+-indicating fluorophores. Biophys J 2000; 79: 39-50.
16. ATP channels. Diabetes 1998; 47: 1412-1418.
17. ATP channels attenuates the ouabain-induced calcium overload in mitochondria. Circ Res 2001; 89: 856-858.
18. 2+ overload with accompanying depolarization of the mitochondrial membrane in the heart. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 192-197.
19. Cribier A, Korsatz L. Koning R, et al. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty. J Am Coll Cardiol 1992; 20: 578-586.
20. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet 1993; 342: 276-277.
21. + channels and their role in cardioprotection. Circ Res 2004; 94: 420-432.
22. ATP channels in cardioprotection. Basic Res Cardiol 2000; 95: 285-289.
23. ATP channels in ischemic cardioprotection. Circulation 2000; 83: 110-114.
24. ATP channels as effectors of human myocardial preconditioning. Cardiovasc Res 2000; 45: 934-940.
25. ATP channels triggers the preconditioned state by generating free radicals. Circ Res 2000; 87: 460-466.
26. Szewczyk A, Czyz A, Nalecz MJ. ATP-regulated potassium channel blocker, glibenclamide, uncouples mitochondria. Pol J Pharmacol 1997; 49: 49-52.
27. ATP channels. Mol Pharmacol 1999; 55: 1000-1005.
28. + channel blocker. Circulation 1994; 90: 700-705.
29. Cleaveland JC, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: two paradoxes revisited. Circulation 1997; 96: 29-32.
30. ATP channels. Br J Pharmacol 2001; 133: 193-199.
31. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439-446.
32. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88: 531-537.
33. ATP channels to gliclazide. Diabetologia 1999; 42:845-848.
34. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004; 18: 113-119.
35. Billman G, Englert HC, Schölkens BA. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part II: effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs. J Pharmacol Exp Ther 1998; 286: 1465-1473.
36. Lomuscio A, Vergani D, Marano L, Castagnone M, Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coron Artery Dis 1994; 5: 767-771.
37. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-124.